CareDx Inc 2022 SR
The report outlines CareDx's sustainability performance for 2022, focusing on its mission to improve transplant patient outcomes. Key highlights include the clinical validation of AlloSure Kidney and the adoption of AlloSure Lung in over 60% of transplant centers. The company achieved $321.8 million in revenue and invested over $90 million in R&D. Social initiatives featured partnerships to improve health equity in underserved communities and support for the ImmunoBill. Environmentally, the company reported its energy and water consumption and implemented waste reduction measures, such as transitioning to LED lighting and reducing plastic use.
Company: CareDx Inc
Sector: Professional & technical services
Country: United States
Year: 2022
Type: SR
Pages: 58
Back to company
CareDx Inc
ESG Report
The report outlines CareDx's sustainability performance for 2022, focusing on its mission to improve transplant patient outcomes. Key highlights include the clinical validation of AlloSure Kidney and the adoption of AlloSure Lung in over 60% of transplant centers. The company achieved $321.8 million in revenue and invested over $90 million in R&D. Social initiatives featured partnerships to improve health equity in underserved communities and support for the ImmunoBill. Environmentally, the company reported its energy and water consumption and implemented waste reduction measures, such as transitioning to LED lighting and reducing plastic use.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Employees